ES2107557T3 - Derivado de acido hidroxamico a base de sulfonamida aromatica. - Google Patents
Derivado de acido hidroxamico a base de sulfonamida aromatica.Info
- Publication number
- ES2107557T3 ES2107557T3 ES92924883T ES92924883T ES2107557T3 ES 2107557 T3 ES2107557 T3 ES 2107557T3 ES 92924883 T ES92924883 T ES 92924883T ES 92924883 T ES92924883 T ES 92924883T ES 2107557 T3 ES2107557 T3 ES 2107557T3
- Authority
- ES
- Spain
- Prior art keywords
- hydroxamic acid
- cell growth
- derivative
- acid based
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UN NUEVO DERIVADO DEL ACIDO HIDROXAMICO QUE CONTIENE UN COMPUESTO REPRESENTADO POR LA FORMULA GENERAL (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO COMO INGREDIENTE ACTIVO, QUE PRESENTA ACTIVIDADES PARA INHIBIR EL CRECIMIENTO CELULAR, LA VASCULARIZACION, ETC. PRESENTA ACTIVIDADES PARA INHIBIR EL CRECIMIENTO DE CELULAS HEMANGIOENDOTELIALES Y EL DESARROLLO DE UN FACTOR DE ADHESION DE LINFOCITOS Y LA DESTRANSFORMACION MEDIANTE UN GEN RAS, INHIBIENDO ASI EL CRECIMIENTO CELULAR Y SIENDO EFICAZ CONTRA LAS INFLAMACIONES Y TUMORES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35079391 | 1991-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2107557T3 true ES2107557T3 (es) | 1997-12-01 |
Family
ID=18412912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92924883T Expired - Lifetime ES2107557T3 (es) | 1991-12-10 | 1992-12-07 | Derivado de acido hidroxamico a base de sulfonamida aromatica. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5534654A (es) |
EP (1) | EP0570594B1 (es) |
JP (1) | JP3342485B2 (es) |
KR (1) | KR100236806B1 (es) |
AT (1) | ATE156116T1 (es) |
DE (1) | DE69221290T2 (es) |
DK (1) | DK0570594T3 (es) |
ES (1) | ES2107557T3 (es) |
GR (1) | GR3024740T3 (es) |
WO (1) | WO1993012075A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165911T3 (es) * | 1994-04-06 | 2002-04-01 | Nippon Shinyaku Co Ltd | Derivado de aminoestilbazol y farmaco. |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
AR011057A1 (es) * | 1997-01-08 | 2000-08-02 | Smithkline Beecham Corp | Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos |
AUPO721997A0 (en) * | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
US6586617B1 (en) * | 1999-04-28 | 2003-07-01 | Sumitomo Chemical Takeda Agro Company, Limited | Sulfonamide derivatives |
JP2001026506A (ja) * | 1999-04-28 | 2001-01-30 | Takeda Chem Ind Ltd | スルホンアミド誘導体 |
WO2000069465A1 (fr) * | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
KR20020070285A (ko) | 1999-11-23 | 2002-09-05 | 메틸진, 인크. | 히스톤 디아세틸라제의 억제제 |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
MXPA02010089A (es) * | 2000-04-13 | 2004-08-19 | Hsc Res Dev Lp | Compuestos para modular la proliferacion celular. |
EP1752446A3 (en) * | 2000-04-13 | 2007-03-21 | HSC Research and Development Limited Partnership | Compounds for modulating cell proliferation |
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | (e)−n−ヒドロキシ−3−(3−スルファモイル−フェニル)アクリルアミド化合物及びその治療用途 |
ATE430567T1 (de) | 2000-09-29 | 2009-05-15 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria |
US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US8026280B2 (en) * | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6727277B1 (en) | 2002-11-12 | 2004-04-27 | Kansas State University Research Foundation | Compounds affecting cholesterol absorption |
EP1567142A4 (en) * | 2002-11-20 | 2005-12-14 | Errant Gene Therapeutics Llc | TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS |
CA2509881A1 (en) * | 2002-12-19 | 2004-07-08 | Elan Pharmaceuticals, Inc. | Substituted n-phenyl sulfonamide bradykinin antagonists |
US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
CA2516842A1 (en) * | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Hydroxamic acid compounds comprising a bicylic heteroaryl group as hdac inhibitors |
WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2005061448A1 (en) * | 2003-12-24 | 2005-07-07 | Monash University | Compositions and methods for treating vascular conditions |
ME02122B (me) * | 2004-03-11 | 2014-02-28 | Altana Pharma Ag | Sulfonilpiroli kao inhibitori hdac |
WO2005092904A1 (en) | 2004-03-26 | 2005-10-06 | Hsc Research And Development Limited Partnership | Novel compounds for modulating cell proliferation |
EP1841747B1 (en) * | 2005-01-14 | 2012-09-05 | SK Biopharmaceuticals Co., Ltd. | Oxazole hydroxamic acid derivatives and use thereof |
JP5119143B2 (ja) | 2005-03-15 | 2013-01-16 | フォーエスシー アクチエンゲゼルシャフト | N−スルホニルピロール類及びヒストンデアセチラーゼインヒビターとしてのそれらの使用 |
WO2006102557A2 (en) * | 2005-03-22 | 2006-09-28 | The President And Fellows Of Harvard College | Treatment of protein degradation disorders |
JP5054671B2 (ja) * | 2005-04-07 | 2012-10-24 | フォーエスシー アクチエンゲゼルシャフト | ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN101268070B (zh) | 2005-09-21 | 2012-09-05 | 奈科明有限责任公司 | 作为hdac抑制剂的磺酰基吡咯 |
EP1928826B1 (en) * | 2005-09-21 | 2013-04-24 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
PT1981877E (pt) | 2006-02-07 | 2012-05-24 | Astellas Pharma Inc | Compostos de n-hidroxiacrilamida |
AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CN101417967A (zh) * | 2007-10-26 | 2009-04-29 | 浙江海正药业股份有限公司 | 组蛋白去乙酰酶抑制剂、其组合物及其应用 |
EP2100878A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Novel method for the production of sulphonylpyrroles as HDAC inhibitors |
AU2009274549B2 (en) | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
KR101546562B1 (ko) * | 2008-10-22 | 2015-08-25 | 어큐셀라 인코포레이티드 | 안과 질환 및 장애 치료용 화합물 |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
US20150045367A1 (en) * | 2011-12-29 | 2015-02-12 | Pharmacyclics, Inc. | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8 |
EA030431B1 (ru) | 2013-12-18 | 2018-08-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | РЕГУЛЯТОРЫ Nrf2 |
TW201639811A (zh) | 2015-03-13 | 2016-11-16 | 佛瑪治療公司 | 作為HDAC8抑制劑之α-桂皮醯胺化合物與組成物 |
JP6786527B2 (ja) | 2015-06-15 | 2020-11-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーター |
SI3307739T1 (sl) | 2015-06-15 | 2021-03-31 | Glaxosmithkline Intellectual Property Development Limited | NRF2 regulatorji |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
KR20240047155A (ko) | 2022-10-04 | 2024-04-12 | 유영훈 | 열선용 커넥션 키트 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2984077B2 (ja) * | 1990-04-19 | 1999-11-29 | 塩野義製薬株式会社 | スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体 |
-
1992
- 1992-12-07 JP JP51077593A patent/JP3342485B2/ja not_active Expired - Fee Related
- 1992-12-07 DK DK92924883.9T patent/DK0570594T3/da active
- 1992-12-07 WO PCT/JP1992/001593 patent/WO1993012075A1/ja active IP Right Grant
- 1992-12-07 ES ES92924883T patent/ES2107557T3/es not_active Expired - Lifetime
- 1992-12-07 DE DE69221290T patent/DE69221290T2/de not_active Expired - Fee Related
- 1992-12-07 AT AT92924883T patent/ATE156116T1/de not_active IP Right Cessation
- 1992-12-07 EP EP92924883A patent/EP0570594B1/en not_active Expired - Lifetime
- 1992-12-07 US US08/098,272 patent/US5534654A/en not_active Expired - Fee Related
- 1992-12-07 KR KR1019930702373A patent/KR100236806B1/ko not_active IP Right Cessation
-
1997
- 1997-09-17 GR GR970402385T patent/GR3024740T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0570594A4 (en) | 1994-05-18 |
KR100236806B1 (ko) | 2000-01-15 |
DE69221290D1 (de) | 1997-09-04 |
GR3024740T3 (en) | 1997-12-31 |
US5534654A (en) | 1996-07-09 |
EP0570594A1 (en) | 1993-11-24 |
DE69221290T2 (de) | 1998-01-15 |
JP3342485B2 (ja) | 2002-11-11 |
DK0570594T3 (es) | 1997-08-25 |
KR930703243A (ko) | 1993-11-29 |
EP0570594B1 (en) | 1997-07-30 |
WO1993012075A1 (en) | 1993-06-24 |
ATE156116T1 (de) | 1997-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2107557T3 (es) | Derivado de acido hidroxamico a base de sulfonamida aromatica. | |
PT976748E (pt) | Derivados de pirrolidina com actividade inibidora de fosfolipase a2 | |
NO950297L (no) | Prolinamidderivater | |
NO900306D0 (no) | Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser. | |
ES8801217A1 (es) | Un procedimiento para la preparacion de un derivado de acido 5-imidazolcarboxilico | |
YU46998B (sh) | Postupak za dobijanje derivata cefema i medjuproizvoda za iste | |
ES2109993T3 (es) | Derivados de 4-desoxi-4-epipodofilotoxina o sus sales farmaceuticamente aceptables. | |
ATE126796T1 (de) | Quinazolinderivate und ihre herstellung. | |
AU7415387A (en) | Imidazolesulfonamide derivatives and herbicides | |
EP1026162A4 (en) | ANTI-RHUMATISMAL AGENT | |
DE69326479D1 (de) | Methotrexat-derivate | |
DE3668888D1 (de) | Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung. | |
MX9206930A (es) | Nuevos compuestos | |
DE69627519D1 (de) | Sesquiterpen-derivate mit antiviraler aktivität | |
ATE192141T1 (de) | Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung | |
DK0466662T3 (da) | 6,7-Disubstituerede-2-aminotetraliner, der er aktive som immunmodulatorer, samt farmaceutiske præparater indeholdende sådanne forbindelser | |
ATE154243T1 (de) | Hemmstoff der blutgefässhypertrophie | |
JPS643164A (en) | Imine compound | |
ES2045335T3 (es) | Un procedimiento para la preparacion de nuevas s-difluorometilhomocisteinas. | |
TH13254A (th) | ฟธาแลซีนชนิดใหม่ที่ประกอบด้วยอีเธอร์หรือไธโออีเธอร์ที่ตำแหน่ง 1-และกรรมวิธีการเตรียม |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 570594 Country of ref document: ES |